If you're looking to put cash into two fantastic biotech stocks that Wall Street seems particularly bullish on, there's one ...

Regeneron topped Wall Street estimates for second-quarter results on Friday, on robust demand for its blockbuster eczema drug ...

Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click ...

Regeneron reports strong Q2 2025 growth with Dupixent sales up 21% and EYLEA HD hitting record highs. Explore key earnings insights and pipeline updates.

Regeneron has received a second complete response letter from the FDA for odronextamab and anticipates delays for Eylea HD ...

REGN stock up as Q2 EPS jumps 12% on strong Eylea HD and Dupixent profits, beating revenue and earnings estimates.

Sanofi missed analyst projections of $1.32 with Q2 earnings per share (EPS) of $1.25. Revenue was €9.89 billion, which was ...

Second quarter 2025 revenues increased 4% to $3.68 billion versus second quarter 2024; Dupixent ® global net sales (recorded by Sanofi) increased 22% to $4.34 billion ; EYLEA HD ...

On Friday, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported second-quarter adjusted earnings of $12.89 per share, up 12% ...

Although Sanofi delivered an earnings miss which still had encouraging results, SNY stock tanked, offering a potential ...

For now, Sanofi’s U.S. inventory is insulating the company from a potential 15% tariff on drugs shipped from the EU.